Australia markets close in 5 hours 56 minutes
  • ALL ORDS

    7,726.80
    -1.70 (-0.02%)
     
  • ASX 200

    7,415.50
    +0.10 (+0.00%)
     
  • AUD/USD

    0.7469
    +0.0001 (+0.02%)
     
  • OIL

    84.01
    +0.25 (+0.30%)
     
  • GOLD

    1,794.30
    -2.00 (-0.11%)
     
  • BTC-AUD

    81,480.32
    -861.15 (-1.05%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • AUD/EUR

    0.6413
    +0.0006 (+0.10%)
     
  • AUD/NZD

    1.0442
    +0.0014 (+0.13%)
     
  • NZX 50

    13,093.24
    -32.76 (-0.25%)
     
  • NASDAQ

    15,355.07
    -134.53 (-0.87%)
     
  • FTSE

    7,204.55
    +14.25 (+0.20%)
     
  • Dow Jones

    35,677.02
    +73.92 (+0.21%)
     
  • DAX

    15,542.98
    +70.38 (+0.45%)
     
  • Hang Seng

    26,126.93
    +109.43 (+0.42%)
     
  • NIKKEI 225

    28,804.85
    +96.25 (+0.34%)
     

IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development

·1-min read

SCHAUMBURG, Ill., September 22, 2021--(BUSINESS WIRE)--IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021. This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide more robust global support for anti-infective product discovery and development. The China facility will provide microbiology testing to support profiling of new antimicrobial products, antimicrobial resistance surveillance, molecular characterization of resistant organisms, and serve as a central laboratory for clinical trials conducted in China.

"We have been working for almost 30 years to maximize our in vitro support for clients who are developing anti-infective products globally. Our facility in China will greatly enhance that effort and support clients wishing to conduct studies in this important market," said Jack L. Johnson, President/CEO of IHMA.

About IHMA:

As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development. IHMA is a premier provider of reference laboratory services to support anti-infective product discovery and development as well as the development of diagnostic devices that detect bacterial resistance to antimicrobial agents and new technologies as they emerge.

For more information, please visit IHMA’s website (www.ihma.com).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005605/en/

Contacts

Darcie Carpenter PhD CIC
Director Global Business Development
+1.530.577.5296
dcarpenter@ihma.com

Ian Morrissey MBA PhD FRSM
Chief Scientific & Development Officer
+44.01279.724929
imorrissey@ihma.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting